CBB1007 trihydrochloride lioxanthin 8-1 Bisindolylmaleimide I (GF109203X)

Bisindolylmaleimide I (GF109203X)

InChiKey: IJVZZGIAELTWBB-BNHRTUKESA-N

The induction of Cryj1-dependent IgE synthesis mediated by SN-4 is suppressed in a concentration-dependent manner by Suplatast tosilate (1 and 10 µg/ml) in autologous B cells

The thalidomide moiety drives proteasomal degradation

1360540-81-3

CBB1007 trihydrochloride lioxanthin 8-1 Bisindolylmaleimide I (GF109203X)CBB1007 is a potent and selective Lysine specific demethylase 1 (LSD1) inhibitor. CBB1007 trihydrochloride is a cell permeable amidino guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5. 27 M for hLSD1). IC50 Value: 5. 27 uM Target: hLSD1 CBB1007 efficiently can block LSD1 mediated demethylation of H3K4Me2 and H3K4Me (IC50 5 M) with no effect on H3K4Me3 and H3K9Me2, and LSD2 and JARID1A